SC
IOVA icon

Saltoro Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Saltoro Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,419
Closed -$1.09M – 117
2021
Q2 		$1.21M Buy
+46,419
New +$1.21M 0.49% 38

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Saltoro Capital's IOVA Position: Q3 2021 in Review

Saltoro Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 46,419 shares — an estimated $1.09M sold.

Saltoro Capital first reported a position in IOVA in Q2 2021 and held it in 1 quarter. The position peaked at $1.21M in Q2 2021. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Saltoro Capital reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Saltoro Capital sold 46,419 Iovance Biotherapeutics shares in Q3 2021, an estimated $1.09M.
  • Saltoro Capital first reported a position in Iovance Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Saltoro Capital's Iovance Biotherapeutics position peaked at $1.21M in Q2 2021.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Saltoro Capital's 13F filing for Q3 2021, filed 12 Nov 2021.